SEC Form 6-K Summary
Business Context and Reporting Period
NervGen Pharma Corp., a Canadian foreign private issuer, filed this Form 6-K for September 2026. On September 25, 2026, its Audit Committee concluded that certain previously issued financial information should no longer be relied upon.
Financial Information Affected
- Audited financial statements for the years ended December 31, 2025 and December 31, 2024.
- Unaudited interim financial information for the quarter ended June 30, 2026.
- The filing does not provide revised revenue, profit, margin, debt, cash balance, or other specific financial amounts.
Material Changes and Restatement
The Company identified non-cash valuation errors in its accounting for stock options and certain outstanding derivative warrant liabilities. The corrective adjustments are expected to reduce previously reported stock-based compensation expense and warrant liabilities, with corresponding changes to unrealized gains and losses on warrant derivatives.
The Company intends to restate the affected annual financial statements through an amendment to its Form 40-F for the year ended December 31, 2025, and the affected interim information through an amendment to its Form 6-K for the quarter ended June 30, 2026. The accounting conclusions and final restatement adjustments remain under evaluation.
Management states that the identified changes will not affect cash position, cash flow, or liquidity. No quantified impact is provided, and the final restated amounts are not yet available.
Guidance, Risks, and Unusual Items
- The principal unusual item is the withdrawal of reliance on previously issued financial information pending restatement.
- The Company discussed the matter with KPMG LLP (Canada), its former independent registered public accounting firm, and KPMG LLP, its current independent registered public accounting firm.
- Forward-looking statements regarding the Restatement and its effect on historical financial statements, cash position, cash flow, and liquidity remain subject to uncertainty.
- Risks include potential changes to the reported historical results and liquidity disclosures, as well as other risks described in the Company’s most recently filed Annual Information Form and 2025 management’s discussion and analysis.
Key Facts for Investors to Verify
- Monitor the amended Form 40-F and amended Form 6-K for the final restated figures and accounting explanations.
- Verify the revised stock-based compensation expense, warrant liabilities, and unrealized warrant-derivative gains or losses.
- Confirm whether management’s conclusion that cash position, cash flow, and liquidity are unaffected remains unchanged after the final restatement.
- Review any auditor communications, updated risk disclosures, or changes to previously issued investor materials.